{"url_path":"/sec/asbp/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1847345/0001493152-26-023802-index.html","accession_number":"0001493152-26-023802","cik":"0001847345","ticker":"ASBP","issuer_name":"Aspire Biopharma Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1847345/0001493152-26-023802-index.html","primary_entity_key":"0001847345","primary_entity_name":"Aspire Biopharma Holdings, Inc."},"word_count":380,"has_tables":true,"body_markdown":"**ITEM\n6. EXHIBITS**\n\n \n\n**Exhibit\nNo.**\n \n**Description**\n\n10.1\n \n[Form of Purchase Agreement (incorporated by reference from Exhibit 10.1 to the Current Report 8-K filed with the SEC on February 20, 2025)](https://www.sec.gov/Archives/edgar/data/1847345/000149315225007732/ex10-1.htm)\n\n10.2\n \n[Form of Leak Out Agreement (incorporated by reference from Exhibit 10.2 to the Current Report 8-K filed with the SEC on February 20, 2025)](https://www.sec.gov/Archives/edgar/data/1847345/000149315225007732/ex10-2.htm)\n\n10.3\n \n[Form of Securities Purchase Agreement (incorporated by reference from Exhibit 10.1 to the Current Report 8-K filed with the SEC on February 21, 2025)](https://www.sec.gov/Archives/edgar/data/1847345/000149315225007898/ex10-1.htm)\n\n10.4\n \n[Form of Debenture (incorporated by reference from Exhibit 10.40 to the Current Report 8-K filed with the SEC on February 21, 2025)](https://www.sec.gov/Archives/edgar/data/1847345/000149315225007898/ex10-40.htm)\n\n10.5\n \n[Purchase Agreement, dated November 11, 2025, between Aspire Biopharma Holdings, Inc. and Arena Business Solutions Global SPC II, Ltd. (incorporated by reference from Exhibit 10.1 to the Current Report on Form 8-K filed November 14, 2025)](https://www.sec.gov/Archives/edgar/data/1847345/000149315225022580/ex10-1.htm)\n\n31.1*\n \n[Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex31-1.htm)\n\n31.2*\n \n[Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex31-2.htm)\n\n32.1**\n \n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32-1.htm)\n\n32.2**\n \n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32-2.htm)\n\n101.INS*\n \nInline\nXBRL Instance Document\n\n101.CAL*\n \nInline\nXBRL Taxonomy Extension Calculation Linkbase Document\n\n101.SCH*\n \nInline\nXBRL Taxonomy Extension Schema Document\n\n101.DEF*\n \nInline\nXBRL Taxonomy Extension Definition Linkbase Document\n\n101.LAB*\n \nInline\nXBRL Taxonomy Extension Labels Linkbase Document\n\n101.PRE*\n \nInline\nXBRL Taxonomy Extension Presentation Linkbase Document\n\n104\n \nCover\nPage Interactive Data File (formatted in Inline XBRL and included as Exhibit 101)\n\n \n\n*\nFiled herewith.\n\n \n\n53\n\n \n\n \n\n**SIGNATURES**\n\n \n\nIn\naccordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned,\nthereunto duly authorized.\n\n \n\n \n**ASPIRE BIOPHARMA HOLDINGS, INC.**\n\n \n \n \n\nDate: May 14, 2026\nBy:\n*/s/ Kraig\nT. Higginson*\n\n \nName: \nKraig T. Higginson\n\n \nTitle:\nChief Executive Officer and Chairman\n\n \n \n(Principal Executive Officer)\n\n \n \n \n\nDate: May 14, 2026\nBy:\n*/s/ Ernest\nJ. Scheidemann*\n\n \nName:\nErnest J. Scheidemann\n\n \nTitle:\nChief Financial Officer\n\n \n \n(Principal Financial and Accounting Officer)\n\n \n\n54"}